Seattle Genetics (SGEN) PT Lowered to $64 at Piper Jaffray

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Seattle Genetics (SGEN) PT Lowered to $64 at Piper Jaffray

Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results

February 7, 2019 4:02 PM EST

-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter-

-ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL-

-Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the First Quarter of 2019-

-Conference Call Today at 4:30 p.m. ET-

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc.(Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December31, 2018. The company also... More